ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "The first half of 2024 was strong as M&As and financings dominate"
Episode Synopsis
Karen Carey, BioWorld managing editor and chief analyst, takes a look at the numbers from the first half of 2024. She finds the first six months to be healthy for the biopharma market while the rest of the year is populated with question marks that include the U.S. presidential election and potential interest rate cuts.
In God we trust